Organization & Developments: NeuroPhage

Parents

NeuroPhage intends to address a broader class of disorders thought to be caused by protein misfolding, including Parkinson’s, amyotrophic lateral sclerosis, and other rare diseases
Plans to use the new money to prepare its lead drug candidate—NPT001 for the treatment of Alzheimer’s disease—for Phase 1 clinical trials within the next two years(2011)
The company’s technology is designed to prevent the buildup of amyloid plaques and to break up existing plaques, which degrade the performance of neurons